Immunosuppression of the elderly kidney transplant recipient

Transplantation

Volumn 84, Issue 3, 2007, Pages 285-291

  Danovitch, Gabriel M ^a   Gill, Jagbir ^a   Bunnapradist, Suphamai ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Aging; Elderly; Immunosuppression; Kidney transplant

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CORTICOSTEROID; CREATININE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; LYMPHOCYTE ANTIBODY; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS; THYMOCYTE ANTIBODY;

ACUTE GRAFT REJECTION; AGING; CLINICAL PROTOCOL; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; ELDERLY CARE; GRAFT RECIPIENT; HIGH RISK PATIENT; HUMAN; IMMUNE FUNCTION TEST; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY TRANSPLANTATION; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; METABOLISM; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; AGING; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; TREATMENT OUTCOME;

EID: 34547876470     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000275423.69689.dc     Document Type: Review

References (63)

1. Danovitch GM, Cohen DJ, Weir MR, et al. Current status of kidney and pancreas transplantation in the United States, 1994-2003. Am J Transplant 2005; 5: 904.
2. Cohen DJ, St Martin L, Christensen LL, Bloom RD, Sung RS. Kidney and pancreas transplantation in the United States, 1995-2004. Am J Transplant 2006; 6: 1153.
3. Danovitch G, Savransky E. Challenges in the counseling and management of older kidney transplant candidates. Am J Kidney Dis 2006; 47: S86.
4. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999; 341: 1725.
5. Johnson DW, Herzig K, Purdie D, et al. A comparison of the effects of dialysis and renal transplantation on the survival of older uremic patients. Transplantation 2000; 69: 794.
6. Oniscu GC, Brown H, Forsythe JL. How great is the survival advantage of transplantation over dialysis in elderly patients? Nephrol Dial Transplant 2004; 19: 945.
7. Fabrizii V, Winkelmayer WC, Klauser R, et al. Patient and graft survival in older kidney transplant recipients: Does age matter? J Am Soc Nephrol 2004; 15: 1052.
8. Herrero JC, Gutierrez E, Martinez A, et al. Results of kidney transplantation in recipients over 70 years of age: Experience at a single center. Transplant Proc 2003; 35: 1675.
9. Rao PS KL, Ashby V, et al. Renal transplantation in patients over 70: Estimation of survival benefit. Am J Transplant 2005; 5: S282.
10. Young CJ, Gaston RS. Understanding the influence of ethnicity on renal allograft survival. Am J Transplant 2005; 5: 2603.
11. Buchler M, Halimi JM, Najjar AA, et al. Living with a functioning kidney transplant at 74 yr or older: A national epidemiological study. Clin Transplant 2004; 18: 681.
12. Meier-Kriesche HU, Port FK, Ojo AO, et al. Effect of waiting time on renal transplant outcome. Kidney Int 2000; 58: 1311.
13. Gill JS, Tonelli M, Johnson N, et al. The impact of waiting time and comorbid conditions on the survival benefit of kidney transplantation. Kidney Int 2005; 68: 2345.
14. Doyle SE, Matas AJ, Gillingham K, Rosenberg ME. Predicting clinical outcome in the elderly renal transplant recipient. Kidney Int 2000; 57: 2144.
15. Oniscu GC, Brown H, Forsythe JL. How old is old for transplantation? Am J Transplant 2004; 4: 2067.
16. Martins PN, Pratschke J, Pascher A, et al. Age and immune response in organ transplantation. Transplantation 2005; 79: 127.
17. Cecka JM. The UPTN/UNOS Renal Transplant Registry. Clin Transpl 2004: 1.
18. Meier-Kriesche HU, Ojo A, Hanson J, et al. Increased immunosuppressive vulnerability in elderly renal transplant recipients. Transplantation 2000; 69: 885.
19. Palomar R, Ruiz JC, Zubimendi JA, et al. Acute rejection in the elderly recipient: Influence of age in the outcome of kidney transplantation. Int Urol Nephrol 2002; 33: 145.
20. Meier-Kriesche HU, Srinivas TR, Kaplan B. Interaction between acute rejection and recipient age on long-term renal allograft survival. Transplant Proc 2001; 33: 3425.
21. Schold JD, Kaplan B, Chumbler NR, et al. Access to quality: Evaluation of the allocation of deceased donor kidneys for transplantation. J Am Soc Nephrol 2005; 16: 3121.
22. Famulski KS, Halloran PF. Molecular events in kidney ageing. Curr Opin Nephrol Hypertens 2005; 14: 243.
23. Meier-Kriesche HU, Ojo AO, Cibrik DM, et al. Relationship of recipient age and development of chronic allograft failure. Transplantation 2000; 70: 306.
24. Meier-Kriesche HU, Cibrik DM, Ojo AO, et al. Interaction between donor and recipient age in determining the risk of chronic renal allograft failure. J Am Geriatr Soc 2002; 50: 14.
25. Danovitch GM. A kidney for all ages. Am J Transplant 2006; 6: 1267.
26. Meier-Kriesche HU, Ojo AO, Hanson JA, Kaplan B. Exponentially increased risk of infectious death in older renal transplant recipients. Kidney Int 2001; 59: 1539.
27. Trouillhet I, Benito N, Cervera C, et al. Influence of age in renal transplant infections: cases and controls study. Transplantation 2005; 80: 989.
28. Meier-Kriesche HU, Friedman G, Jacobs M, et al. Infectious complications in geriatric renal transplant patients: Comparison of two immunosuppressive protocols. Transplantation 1999; 68: 1496.
29. Danpanich E, Kasiske BL. Risk factors for cancer in renal transplant recipients. Transplantation 1999; 68: 1859.
30. Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant 2004; 4: 905.
31. Meier-Kriesche HU, Kaplan B. Immunosuppression in elderly renal transplant recipients: Are current regimens too aggressive? Drugs Aging 2001; 18: 751.
32. Bernardo JF, McCauley J. Drug therapy in transplant recipients: Special considerations in the elderly with comorbid conditions. Drugs Aging 2004; 21: 323.
33. Kaplan B, Meier-Kriesche HU, Friedman G, et al. The effect of renal insufficiency on mycophenolic acid protein binding. J Clin Pharmacol 1999; 39: 715.
34. Zeeh J, Platt D. The aging liver: Structural and functional changes and their consequences for drug treatment in old age. Gerontology 2002; 48: 121.
35. Reference deleted in proof.
36. Bourdage JS, Hamlin DM. Comparative polyclonal antithymocyte globulin and antilymphocyte/antilymphoblast globulin anti-CD antigen analysis by flow cytometry. Transplantation 1995; 59: 1194.
37. Zand MS, Vo T, Huggins J, et al. Polyclonal rabbit antithymocyte globulin triggers B-cell and plasma cell apoptosis by multiple pathways. Transplantation 2005; 79: 1507.
38. Woodside KJ, Hu M, Meng T, et al. Differential effects of interleukin-2 blockade on apoptosis in naive and activated human lymphocytes. Transplantation 2003; 75: 1631.
39. Goggins WC, Pascual MA, Powelson JA, et al. A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients. Transplantation 2003; 76: 798.
40. Brennan DC, Flavin K, Lowell JA, et al. A randomized, double-blinded comparison of Thymoglobulin versus Atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation 1999; 67: 1011.
41. Brennan DC, Daller JA, Lake KD, et al. Rabbit antithymocyte globulin versus basiliximab in renal transplantation. N Engl J Med 2006; 355: 1967.
42. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323: 1723.
43. Paya CV, Fung JJ, Nalesnik MA, et al. Epstein-Barr virus-induced post-transplant lymphoproliferative disorders. ASTS/ASTP EBV-PTLD Task Force and The Mayo Clinic Organized International Consensus Development Meeting. Transplantation 1999; 68: 1517.
44. Thistlethwaite JR Jr, Stuart JK, Mayes JT, et al. Complications and monitoring of OKT3 therapy. Am J Kidney Dis 1988; 11: 112.
45. Opelz G, Schwarz V, Henderson R, et al. Non-Hodgkin's lymphoma after kidney or heart transplantation: Frequency of occurrence during the first posttransplant year. Transpl Int 1994; 7 Suppl 1: S353.
46. Cherikh WS, Kauffman HM, McBride MA, et al. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003; 76: 1289.
47. Mourad G, Rostaing L, Legendre C, et al. Sequential protocols using basiliximab versus antithymocyte globulins in renal-transplant patients receiving mycophenolate mofetil and steroids. Transplantation 2004; 78: 584.
48. Lebranchu Y, Bridoux F, Buchler M, et al. Immunoprophylaxis with basiliximab compared with antithymocyte globulin in renal transplant patients receiving MMF-containing triple therapy. Am J Transplant 2002; 2: 48.
49. Johnson DW, Nicol DL, Preston JM, et al. Use of mycophenolate mofetil in immunosuppressive protocols in elderly renal transplant recipients. Transplantation 2003; 76: 619.
50. Sureshkumar KK, Nghiem DD. Use of mycophenolate mofetil in immunosuppressive protocols in elderly renal transplant recipients. Transplantation 2003; 76: 441.
51. Meier-Kriesche HU, Morris JA, Chu AH, et al. Mycophenolate mofetil vs azathioprine in a large population of elderly renal transplant patients. Nephrol Dial Transplant 2004; 19: 2864.
52. Meier-Kriesche HU, Li S, Gruessner RW, et al. Immunosuppression: evolution in practice and trends, 1994-2004. Am J Transplant 2006; 6: 1111.
53. Shah T, Kasravi A, Huang E, et al. Risk factors for development of new-onset diabetes mellitus after kidney transplantation. Transplantation 2006; 82: 1673.
54. Arbogast H, Huckelheim H, Schneeberger H, et al. A calcineurin antagonist-free induction/maintenance strategy for immunosuppression in elderly recipients of renal allografts from elderly cadaver donors: Long-term results from a prospective single centre trial. Clin Transplant 2005; 19: 309.
55. Stangl M, Zerkaulen T, Theodorakis J, et al. Influence of brain death on cytokine release in organ donors and renal transplants. Transplant Proc 2001; 33:1284.
56. Emparan C, Wolters H, Laukotter M, Senninger N. Long-term results of calcineurin-free protocols with basiliximab induction in "old-to-old" programs. Transplant Proc 2004; 36: 2646.
57. Segoloni GP, Messina M, Squiccimarro G, et al. Preferential allocation of marginal kidney allografts to elderly recipients combined with modified immunosuppression gives good results. Transplantation 2005; 80: 953.
58. Kreis H, Oberbauer R, Campistol JM, et al. Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal. J Am Soc Nephrol 2004; 15: 809.
59. Koehl GE, Andrassy J, Guba M, et al. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 2004; 77: 1319.
60. Kahan BD, Yakupoglu YK, Schoenberg L, et al. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation 2005; 80: 749.
61. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352: 1317.
62. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: Results from five multicenter studies. Clin Transplant 2004; 18: 446.
63. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80: 883.